Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Transcode Therapeutics Inc RNAZ

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique... see more

Bullboard (NDAQ:RNAZ)

View:
User Avatar Image
(279)
•••
  • whytestocksX
Post by whytestockson Sep 05, 2024 12:00pm

TransCode Therapeutics Awarded $2 Million NIH Grant to Suppo

News; $RNAZ TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateBOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ ...more  
User Avatar Image
(9)
•••
  • MikeTesterX
Post by MikeTesteron Aug 03, 2024 1:49am

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Advancing Targete

https://beyondspx.com/2024/08/02/transcode-therapeutics-inc-nasdaqrnaz-advancing-targeted-rna-therapeutics-through-innovative-delivery/
User Avatar Image
(279)
•••
  • whytestocksX
Post by whytestockson Jun 10, 2024 10:00am

Nasdaq Determines That TransCode Therapeutics Has Regained C

News; $RNAZ Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsBOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq ...more  
Post by Tarbabyon Feb 08, 2024 10:39am

Total Shares Issued

I believe Stockhouse is wrong in their share count. The company recently issued ove 7 million shares in a money raise. But the msrket cap is still extremely low for a cutting edge cancer study.. Its a ...more  
Post by Tarbabyon Feb 08, 2024 10:35am

Total Shares Issued

I believe Stockhouse is wrong in their share count. The company recently issued ove 7 million shares in a money raise. But the msrket cap is still extremely low for a cutting edge cancer study.. Its a ...more  
Post by Tarbabyon Feb 07, 2024 1:03pm

Collaboration Looks Good

I teally like the collaboration agreement. It really lends credibility to their cancer treatment protocol... Good work team..! Im a buyer. Cheers
User Avatar Image
(72)
•••
  • IseneschalX
Post by Iseneschalon Jan 19, 2024 1:33pm

RNAZ....2 x's tap on L.O.D 74

I say 56 close
User Avatar Image
(72)
•••
  • IseneschalX
Post by Iseneschalon Jan 19, 2024 10:51am

RNAZ..... This ain't the bottom

Bets ????
User Avatar Image
(72)
•••
  • IseneschalX
Post by Iseneschalon Jan 19, 2024 7:24am

RNAZ....... Fryday

Literally
User Avatar Image
(72)
•••
  • IseneschalX
Post by Iseneschalon Jan 18, 2024 3:41pm

RNAZ....P.O being priced

who know at what price This is all smoke & mirrors
User Avatar Image
(72)
•••
  • IseneschalX
Post by Iseneschalon Jan 18, 2024 10:50am

RNAZ....total manip & MM antics

Do some reasearch ....LoL
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities